Stockscreener 앱 받기
1.82
13.75%
0.22
시간 외 거래:
1.82
전일 마감가:
$1.60
열려 있는:
$1.64
하루 거래량:
1.98M
Relative Volume:
1.18
시가총액:
$268.07M
수익:
$72,500
순이익/손실:
$-45.96M
주가수익비율:
-2.671
EPS:
-0.6814
순현금흐름:
$-44.56M
1주 성능:
+12.35%
1개월 성능:
-26.32%
6개월 성능:
+80.20%
1년 성능:
+136.39%
1일 변동 폭
$1.62
$1.88
1주일 범위
$1.54
$1.88
52주 변동 폭
$0.7406
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
1.82 | 238.61M | 72,500 | -45.96M | -44.56M | -0.6814 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | 재개 | H.C. Wainwright | Buy |
| 2025-05-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-02-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-06 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | 개시 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-04-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-06-05 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-01-29 | 개시 | Robert W. Baird | Outperform |
| 2018-12-10 | 개시 | Credit Suisse | Outperform |
| 2018-07-13 | 개시 | BMO Capital Markets | Outperform |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-28 | 개시 | SunTrust | Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Inflarx Nv 주식(IFRX)의 최신 뉴스
InflaRx N.V. Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineEarnings Growth Forecast - newsline.com
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical Progress; Stock SlipsPost-Announcement Reaction - newsline.com
What Do Analysts Say About InflaRx N.V. (IFRX)? - Insider Monkey
IFRX Q4 2025 Earnings: Narrower-than-Expected Loss Fails to Stem Stock DeclinePre-Earnings Drift - newsline.com
InflaRx prices $150 million share offering at $2 per share - Investing.com
InflaRx to develop izicopan for kidney disease treatment - Investing.com
InflaRx prices $150 million share offering at $2 per share By Investing.com - Investing.com Australia
INFLARX NV (IFRX) Stock Chart - ChartMill
InflaRx stock surges on AAV drug development plan - Investing.com
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline - MSN
InflaRx NV stock (NL0012661870): Nasdaq-listed biotech trades lower ahead of next earnings update - AD HOC NEWS
Raymond James Upgrades InflaRx Following Clinical Shift - asatunews.co.id
Wall Street Firms Upgrade InflaRx Following Strategic Kidney Disease Focus - HarianBasis.co
InflaRx N.V. (IFRX) Edges Higher with Modest Gains, Tests Key Resistance ZoneHigh Volume Stocks - The Legal Advocate
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now - Yahoo Finance
5 Most Volatile Penny Stocks to Buy Now - Insider Monkey
InflaRx N.V. Shows Resilience: IFRX Stock Edges Higher on Modest VolumePassive Flow - newsline.com
InflaRx N.V. (IFRX) Tumbles 7% as Shares Test Key Support LevelsSmart Beta Flow - newsline.com
InflaRx (IFRX) Surges Nearly 5%, Testing Key Resistance at $2.88Last Point Support - thelegaladvocate.com
IFRX - Finviz
InflaRx (IFRX) Q4 2025 Earnings: Slight EPS Beat Amid Pre‑Revenue PhaseStrong Earnings Momentum - The Legal Advocate
InflaRx N.V. (IFRX) Q4 2025 Earnings: Narrower Loss and Pipeline Progress Lift Sentiment - thelegaladvocate.com
InflaRx N.V. (IFRX) Surges 7.5% as Shares Test Key Resistance LevelWave Equality - The Legal Advocate
Long term debt to total assets ratio of InflaRx N.V. – HAM:IF0 - TradingView
Discontinued operations of InflaRx N.V. – HAM:IF0 - TradingView
EBIT per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx N.V. Cash Flow – HAM:IF0 - TradingView
InflaRx N.V. Balance Sheet – HAM:IF0 - TradingView
InflaRx N.V. Statistics – HAM:IF0 - TradingView
Non-controlling/minority interest of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx N.V. (IFRX) Stock Analysis: +2.11% Gain — What to Watch 2026-05-20Zigzag Correction - newsline.com
InflaRx NV stock (NL0012661870): what’s behind the latest trading volatility after Gohibic’s slo - AD HOC NEWS
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InflaRx to develop izicopan for kidney disease treatment By Investing.com - Investing.com Nigeria
InflaRx N.V. (IFRX) Up +1.26% — Is There More Room to Run? 2026-05-18Upthrust Pattern - newsline.com
InflaRx NV stock (NL0012661870): May data from a recent YTD ranking - AD HOC NEWS
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Farallon funds and managers report shared stakes in InflaRx (IFRX) - Stock Titan
InflaRx NV (IFRX) price target decreased by 16.67% to 7.29 - MSN
Raymond James upgrades InflaRx NV (IFRX) - MSN
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential - Investing.com UK
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential By Investing.com - Investing.com South Africa
InflaRx NV Stock (IFRX): Favorable Izicopan Data Released - AD HOC NEWS
TradingKey - TradingKey
Inflarx Nv (IFRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):